乳腺癌分子分型与临床病理参数的关系及预后  

Correlation between molecular subtypes, clinicopathological parameters and prognosis of breast cancer

作　　者：李杰宝[1] 喻晓程 田野[1] Li Jiebao;Yu Xiaocheng;Tian Ye(Department of Thyroid - Breast Surgery, Wuhan First Hospital, Wuhan 430030, Chin)

机构地区：[1]武汉市第一医院甲乳外科,430030

出　　处：《中华实验外科杂志》2018年第6期1027-1029,共3页Chinese Journal of Experimental Surgery

基　　金：2015年武汉市卫计委临床医学课题（WX15B17）

摘　　要：目的探讨新型乳腺癌分子分型与临床病理参数的关系及预后。方法选取乳腺癌126例患者为研究对象。根据人表皮生长因子受体2（Her-2）、孕激素受体（PR）、雌激素受体（ER）和细胞核增殖抗原（Ki-67）的免疫组织化学结果将乳腺癌分为三阴性型、Her-2过表达型、LuminalB型和LuminalA型；采用检验分析乳腺癌新型分子分型与临床病理参数之间的关系；采用Kaplan-Meier法分析乳腺癌新型分子分型与乳腺癌患者的总体生存率（0S）之间的关系。结果126例乳腺癌患者中，三阴性型、Her-2过表达型、LuminalB型和LuminalA型分别占28．57％、16．67％、23．81％和30．95％。不同分子亚型的乳腺癌患者的年龄、肿瘤大小、是否绝经、淋巴结是否转移以及术后分期等临床病理参数之间的差异无统计学意义。三阴性型乳腺癌患者发生复发转移的概率以及因此引起的死亡率均显著高于其他3组（P=0．001），即三阴性型乳腺癌的预后最差。不同分子亚型的乳腺癌患者的总生存率之间的差异有统计学意义（P=0．034）。结论新型乳腺癌分子分型有助于评估乳腺癌预后。Objective To investigate the correlation between new molecular subtypes, cllnlcopath- ologieal parameters and prognosis of breast cancer. Methods A total of 126 patients diagnosed with breast cancer at the Wuhan First Hospital from 2008 to 2017 were selected as the study subjects. The breast cancer was classified into Triple - negative breast cancer subtype, human epidermal growth factor receptor - 2 （Her- 2） over- expression subtype, Luminal B subtype and Luminal A subtype, according to the immu- nohistochemical results of Her- 2, progesterone receptor （PR） , estrogen receptor （ER） and proliferation cell nuclear antigen （ Ki - 67 ）. The correlation between new molecular subtypes and clinicopathologieal pa- rameters of breast cancer were analyzed and compared through Chi - square test. The correlation between new molecular subtypes of breast cancer and overall survival rate of breast cancer patients was analyzed through Kaplan- Meier method. Results In 126 cases of breast cancer, Luminal A subtype, Luminal B subtype, Her - 2 over - expression subtype and Triple - negative breast cancer subtype accounted for 28.57% , 16. 67%, 23.81% and 30. 95%, respectively. No statistically significant difference existe a- mong molecular subtypes of breast cancer as for the age of patients, size of tumor, menopausal status, lymph node metastasis, postoperative pathological stages and other clinical pathological parameters. The probability of recurrence and metastasis in Triple - negative breast cancer patients and the consequent mor- tality were significantly higher than those of the other three groups （P = 0. 001 ）. The prognosis of Triple - negative breast cancer was the worst. There was statistically significant differences in the overall survival rate among breast cancer patients with differences molecular subtypes （P = 0. 034）. Conclusion The mo- lecular classification of new breast cancer can help to evaluate the prognosis of breast cancer.

关 键 词：乳腺癌 新型分子分型 临床病理参数 

分 类 号：R737.9[医药卫生—肿瘤]